| Patent Number |
Title Of Patent |
Date Issued |
| 8105774 |
PGC-1.beta., PGC-1 homologue and uses therefor |
January 31, 2012 |
| The invention provides isolated nucleic acid molecules, designated PGC-1.beta. nucleic acid molecules, which encode novel PGC-1 related coactivator molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1.beta. nucleic a |
| 7947652 |
Compositions and methods for modulating PGC-1.alpha. to treat huntington's disease |
May 24, 2011 |
| The present invention provides methods for modulating mitochondrial function, modulating lesion formation in the brain, modulating neurite growth, modulating neuronal degeneration, and treating and preventing neurological diseases or disorders comprising modulating the expression or |
| 7691578 |
Methods and compositions for treating obesity |
April 6, 2010 |
| The present invention relates to therapeutic compositions for treating or preventing obesity and obesity-related disorders in a subject. The present invention also relates to the use of PGC-1 expression levels to determine the safe dosage range for known or putative respiration uncou |
| 7635708 |
Methods and pharmaceutical compositions for inhibiting tumor cell growth |
December 22, 2009 |
| The present invention is based on the finding that activation of PPAR.gamma. plays a key role in inducing growth arrest and differentiation of certain actively proliferating cells. We show that administration of PPAR.gamma. agonists, such as thiazolidinedione ligands (TZDs), is effec |
| 7371529 |
Methods and compositions for modulating gluconeogenesis using PGC-1 |
May 13, 2008 |
| The invention provides novel methods and compositions for modulating gluconeogenesis through modulation of PGC-1 activity or expression. Also provided are methods for identifying compounds that modulate gluconeogenesis through modulation of PGC-1 activity or expression, as well as me |
| 7354738 |
PGC-1.beta., a novel PGC-1 homologue and uses therefor |
April 8, 2008 |
| The invention provides isolated nucleic acid molecules, designated PGC-1.beta. nucleic acid molecules, which encode novel PGC-1 related coactivator molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1.beta. nucleic a |
| 7250283 |
PGC-1 isoforms and uses therefor |
July 31, 2007 |
| The invention provides isolated nucleic acid molecules, designated PGC-1b and PGC-1c nucleic acid molecules, which encode novel isoforms of PGC-1 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid |
| 7091006 |
PGC-1.beta., a novel PGC-1 homologue and uses therefor |
August 15, 2006 |
| The invention provides isolated nucleic acid molecules, designated PGC-1.beta. nucleic acid molecules, which encode novel PGC-1 related coactivator molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1.beta. nucleic a |
| 6974671 |
Methods for indentifying compounds that modulate gluconeogenesis through the binding of CREB to |
December 13, 2005 |
| In accordance with the present invention, it has been discovered that CREB regulates hepatic gluconeogenesis via the co-activator, PGC-1. PGC-1 potentiated glucocorticoid induction of the gene for PEPCK, the rate limiting enzyme in gluconeogenesis, via the glucocorticoid response unit |
| 6908987 |
PCG-1, a novel brown fat PPAR.gamma. coactivator |
June 21, 2005 |
| The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention |
| 6872391 |
PGC-1, a novel brown fat PPAR.gamma. coactivator |
March 29, 2005 |
| The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention |
| 6586455 |
Treatment of liposarcomas using a combination of thiazolidinediones and retinoid X receptor sele |
July 1, 2003 |
| In accordance with the present invention, it has been discovered that PPAR.gamma. is expressed consistently in each of the major histologic types of human liposarcoma. It has further been discovered that maximal activation of PPAR.gamma. with exogenous ligand (a thiazolidinedione or |
| 6552055 |
Methods and pharmaceutical compositions for inhibiting tumor cell growth |
April 22, 2003 |
| The present invention is based on the finding that activation of PPAR.gamma. plays a key role in inducing growth arrest and differentiation of certain actively proliferating cells. We show that administration of PPAR.gamma. agonists, such as thiazolidinedione ligands (TZDs), is effec |
| 6525178 |
PGC-1, a novel brown fat PPARgamma coactivator |
February 25, 2003 |
| The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention |
| 6426411 |
PGC-1, a novel brown fat ppar.gamma. coactivator |
July 30, 2002 |
| The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention |
| 6242196 |
Methods and pharmaceutical compositions for inhibiting tumor cell growth |
June 5, 2001 |
| A method for inhibiting proliferation of a PPAR .gamma.-responsive hyperproliferative cell which comprises the step of contacting the cell with (I) an inhibitory amount of a PPAR.gamma. agonist and (II) a MAP kinase inhibitor is disclosed. A method for treating or prophylactically pr |
| 6166192 |
PGC-1, a novel brown fat PPAR.gamma. coactivator |
December 26, 2000 |
| The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention |
| 6015558 |
Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-.alp |
January 18, 2000 |
| An induction of TNF-.alpha. mRNA expression has been observed in adipose tissue from four different insulin resistant rodent models of obesity and diabetes. TNF-.alpha. protein was also elevated locally and systemically. Neutralization of TNF-.alpha. in obese fa/fa rats caused a signific |
| 5730975 |
Treatment of insulin resistance in obesity linked type II diabetes using antagonist to TNF-alpha |
March 24, 1998 |
| An induction of TNF-.alpha. mRNA expression has been observed in adipose tissue from four different insulin resistant rodent models of obesity and diabetes. TNF-.alpha. protein was also elevated locally and systemically. Neutralization of TNF-.alpha. in obese fa/fa rats caused a signific |
| 5476926 |
Adipocyte-specific DNA sequences and use thereof in the production of transgenic animals exhibit |
December 19, 1995 |
| Regulatory DNA sequences are provided, which are obtained from the 5' flanking region of genes which are expressed primarily in differentiated adipose tissue. These DNA sequences are largely responsible for driving the expression of endogenous genes specifically in adipose tissue in vivo |
| 5306729 |
Method for effecting vasodilation with monoglycerides |
April 26, 1994 |
| The invention provides a novel method of effecting vasodilation in a warm-blooded animal in need of such treatment and involves administering to a warm-blooded animal an effective amount of a vasodilatory monoglyceride of the formula: ##STR1## wherein R is a straight or branched |
